Novartis is trading 3.18% higher at $161.04 in pre-market after raising its full-year core operating income outlook. - October 27 third-quarter core earnings beat expectations; the outlook shifted from a decline to in-line-to-low-single-digit growth. - Strong demand for Kisqali and other priority brands helped offset generic erosion; healthcare-sector strength provided additional support. - Novartis also disclosed a $1.9 billion del-desiran impairment, weighing on reported profit.